Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
- Autores
- Spaapen, Robbert; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long; Zheng, Yan; Fu, Yang Xin; Luo, Xixi; Cohen, Kenneth S.; Gajewski, Thomas F.
- Año de publicación
- 2014
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo.
Fil: Spaapen, Robbert . University Of Chicago; Estados Unidos
Fil: Leung, Michael Y. K.. University Of Chicago; Estados Unidos
Fil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. University Of Chicago; Estados Unidos
Fil: Kline, Justin P.. University Of Chicago; Estados Unidos
Fil: Zhang, Long . University Of Chicago; Estados Unidos
Fil: Zheng, Yan . University Of Chicago; Estados Unidos
Fil: Fu, Yang Xin. University Of Chicago; Estados Unidos
Fil: Luo, Xixi . University Of Chicago; Estados Unidos
Fil: Cohen, Kenneth S. . University Of Chicago; Estados Unidos
Fil: Gajewski, Thomas F. . University Of Chicago; Estados Unidos - Materia
-
Interferon Beta
Tumor
Vasculature
Therapy
Experimental Melanoma - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/7346
Ver los metadatos del registro completo
id |
CONICETDig_bc659ef80c45c83c267c27974ef267d3 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/7346 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculatureSpaapen, Robbert Leung, Michael Y. K.Fuertes, Mercedes BeatrizKline, Justin P.Zhang, Long Zheng, Yan Fu, Yang XinLuo, Xixi Cohen, Kenneth S. Gajewski, Thomas F. Interferon BetaTumorVasculatureTherapyExperimental Melanomahttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo.Fil: Spaapen, Robbert . University Of Chicago; Estados UnidosFil: Leung, Michael Y. K.. University Of Chicago; Estados UnidosFil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. University Of Chicago; Estados UnidosFil: Kline, Justin P.. University Of Chicago; Estados UnidosFil: Zhang, Long . University Of Chicago; Estados UnidosFil: Zheng, Yan . University Of Chicago; Estados UnidosFil: Fu, Yang Xin. University Of Chicago; Estados UnidosFil: Luo, Xixi . University Of Chicago; Estados UnidosFil: Cohen, Kenneth S. . University Of Chicago; Estados UnidosFil: Gajewski, Thomas F. . University Of Chicago; Estados UnidosAmer Assoc Immunologists2014-10-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/7346Spaapen, Robbert ; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long ; et al.; Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature; Amer Assoc Immunologists; Journal Of Immunology; 193; 8; 15-10-2014; 4254-42600022-17671550-6606enginfo:eu-repo/semantics/altIdentifier/url/http://dx.doi.org/10.4049/jimmunol.1401109info:eu-repo/semantics/altIdentifier/url/http://www.jimmunol.org/content/193/8/4254.longinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:40Zoai:ri.conicet.gov.ar:11336/7346instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:40.599CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
title |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
spellingShingle |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature Spaapen, Robbert Interferon Beta Tumor Vasculature Therapy Experimental Melanoma |
title_short |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
title_full |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
title_fullStr |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
title_full_unstemmed |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
title_sort |
Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature |
dc.creator.none.fl_str_mv |
Spaapen, Robbert Leung, Michael Y. K. Fuertes, Mercedes Beatriz Kline, Justin P. Zhang, Long Zheng, Yan Fu, Yang Xin Luo, Xixi Cohen, Kenneth S. Gajewski, Thomas F. |
author |
Spaapen, Robbert |
author_facet |
Spaapen, Robbert Leung, Michael Y. K. Fuertes, Mercedes Beatriz Kline, Justin P. Zhang, Long Zheng, Yan Fu, Yang Xin Luo, Xixi Cohen, Kenneth S. Gajewski, Thomas F. |
author_role |
author |
author2 |
Leung, Michael Y. K. Fuertes, Mercedes Beatriz Kline, Justin P. Zhang, Long Zheng, Yan Fu, Yang Xin Luo, Xixi Cohen, Kenneth S. Gajewski, Thomas F. |
author2_role |
author author author author author author author author author |
dc.subject.none.fl_str_mv |
Interferon Beta Tumor Vasculature Therapy Experimental Melanoma |
topic |
Interferon Beta Tumor Vasculature Therapy Experimental Melanoma |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo. Fil: Spaapen, Robbert . University Of Chicago; Estados Unidos Fil: Leung, Michael Y. K.. University Of Chicago; Estados Unidos Fil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. University Of Chicago; Estados Unidos Fil: Kline, Justin P.. University Of Chicago; Estados Unidos Fil: Zhang, Long . University Of Chicago; Estados Unidos Fil: Zheng, Yan . University Of Chicago; Estados Unidos Fil: Fu, Yang Xin. University Of Chicago; Estados Unidos Fil: Luo, Xixi . University Of Chicago; Estados Unidos Fil: Cohen, Kenneth S. . University Of Chicago; Estados Unidos Fil: Gajewski, Thomas F. . University Of Chicago; Estados Unidos |
description |
Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-10-15 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/7346 Spaapen, Robbert ; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long ; et al.; Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature; Amer Assoc Immunologists; Journal Of Immunology; 193; 8; 15-10-2014; 4254-4260 0022-1767 1550-6606 |
url |
http://hdl.handle.net/11336/7346 |
identifier_str_mv |
Spaapen, Robbert ; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long ; et al.; Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature; Amer Assoc Immunologists; Journal Of Immunology; 193; 8; 15-10-2014; 4254-4260 0022-1767 1550-6606 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://dx.doi.org/10.4049/jimmunol.1401109 info:eu-repo/semantics/altIdentifier/url/http://www.jimmunol.org/content/193/8/4254.long |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Amer Assoc Immunologists |
publisher.none.fl_str_mv |
Amer Assoc Immunologists |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269299723468800 |
score |
13.13397 |